Preamble
The American College of Cardiology (ACC) and the American Heart Association (AHA) recognize the importance of refining the lexicon used to describe the process and outcomes of clinical care, whether in randomized trials, observational studies, registries, or quality-improvement initiatives. Broad professional agreement on a common vocabulary with common definitions will facilitate cross-study comparisons or, when advantageous, combining of data across studies and will improve the assessment of any project's generalizability to clinical practice. To further efforts aimed at standardizing such a lexicon, the ACC and AHA have undertaken to develop and publish clinical data standards, sets of standardized data elements and corresponding definitions that can be used in a variety of data collection efforts for a range of cardiovascular conditions. It is hoped that these clinical data standards will: 1. Improve cross-comparison of results and clinical outcomes between different trials and registries. 2. Facilitate the development and conduct of future registries, at both hospital and national levels, by providing a list of major variables, outcomes, and definitions. 3. Facilitate measurement for quality-improvement programs. 4. Become the basis for a standardized charting process with the anticipation that medical charting will progress to an electronic format. The ACC/AHA Task Force on Clinical Data Standards makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or a personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur.
The ACC/AHA Task Force on Clinical Data Standards selects cardiovascular conditions and procedures that would benefit from the creation of a data standard set. Experts in the subject are selected to examine/consider existing data standards and develop a comprehensive, yet not exhaustive, data standard set. Users should understand that when they undertake a data collection effort, only a subset may be needed, or conversely, they may want to consider whether it may be necessary to collect some elements not listed. For example, in the setting of a randomized clinical trial of a new drug, additional information would likely be required regarding study procedures and drug therapies.
The ACC and AHA aim to standardize the language used to describe cardiovascular diseases and procedures, enhance consistency in cardiology, and increase opportunities for sharing data across various data sources. The ultimate goal of ACC/AHA clinical data standards is to contribute to the infrastructure necessary for accomplishing the ACC/AHA's mission of fostering optimal cardiovascular care and disease prevention.
The ACC and AHA support the goals of its members to improve cardiovascular care and disease prevention through professional education, promotion of research, development of guidelines and standards for cardiovascular care, and the fostering of policy that supports optimal patient outcomes. The ACC and AHA recognize the importance of the use of clinical data for patient management, in the assessment of patient outcomes, and in research efforts focused on improving clinical treatment of patients.
As a component of this objective, the ACC/AHA clinical data standards concentrate on the identification, definition, and standardization of data that correspond to various clinical topics in cardiology. The primary goal of clinical data standards is to assist in the collection of data by providing an initial platform of data elements and corresponding definitions applicable to various disease conditions in cardiology.
These key elements and definitions are a compilation of variables applicable in the measurement of patient clinical management and outcomes and for research and epidemiological assessments.
The Health Insurance Portability and Accountability Act (HIPAA) privacy regulations, which went into effect in April 2003, have heightened all practitioners' awareness of our professional commitment to safeguard our patients' privacy. Our goal is to treat every patient's health information with the same respect and courtesy as their person. The HIPAA privacy regulations (http://www.hhs.gov/ocr/combinedregtext. pdf, page 31) specify which information elements are considered "protected health information." These elements may not be disclosed to third parties (including registries and research studies) without the patient's written permission, and research studies that use protected health information must be reviewed by an Institutional Review Board or a Privacy Board.
We have included identifying information in all clinical data standards to facilitate uniform collection of these elements when appropriate. For example, a longitudinal clinic database may contain these elements, because access is restricted to the patient's caregivers. On the other hand, registries may not contain protected health information unless specific permission is granted by each patient. These fields are indicated as protected health information (PHI) in the data standards.
Our understanding of the importance of data element standardization, derives from experience with clinical care, clinical research, and quality-performance measurement. In clinical care, caregivers communicate with each other through a common vocabulary. The integrity of clinical research depends in large part on firm adherence to prespecified procedures for patient enrollment and follow-up; these procedures are guaranteed through careful attention to definitions enumerated in the study design and case report forms. When data elements and definitions are standardized across studies, comparison, pooled analysis, and meta-analysis are facilitated, thus deepening our understanding of individual clinical trials.
The recent development of quality-performance measurement initiatives, particularly those for which comparison of providers is an implicit or explicit aim, has further raised awareness among the professional community about the importance of data standards. For the first time, a wide audience, including nonmedical professionals such as payers,
I. Introduction
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Prevalence of AF increases with age, reaching as high as 9% in octogenarians. [1] [2] [3] [4] New pharmacological and nonpharmacological treatments, as well as results from some large clinical trials, [5] [6] [7] have increased interest in the management of AF. To address this increased need and interest, the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) jointly released the ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation. 8 The ACC and AHA are following this effort with the ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial Fibrillation. AF is one of several conditions identified for development of clinical data standards by the ACC/AHA Task Force on Clinical Data Standards and is preceded by clinical data standards on acute coronary syndrome.
A. Purpose
The ACC/AHA Atrial Fibrillation Data Standards Writing Committee proceeded to develop data elements and definitions with the goal that they may be useful in a variety of circumstances:
• Clinical programs, where many providers and health plans work together to achieve specific goals for the care of patients with AF. Data standards will assist in the organization and design of electronic medical information initiatives, such as electronic medical records, pharmacy and other clinical databases, or computerized decision support. • Clinical research, including prospective registries and randomized controlled trials (RCTs). Meta-analyses of RCTs would be particularly strengthened by the use of standardized data for key variables. • Quality-performance measurement initiatives. Data standards will especially facilitate interpretation for nonmedical users, such as payers, regulators, and consumers.
These data standards were designed to facilitate the above initiatives. Because they were developed to support many varied uses, they were not designed to provide an operational format for any one specific use. Thus, the definitions are often stated in a more general fashion than will be appropriate for certain purposes. More specific operational definitions likely will be used for actual data collection, with these data standards providing a uniform guide for their development. In addition, because the data standards were developed for potential application in varied environments, all elements are not expected to pertain to each application.
II. Methodology

A. Writing Committee Composition
The ACC/AHA Writing Committee to Develop Clinical Data Standards for Atrial Fibrillation included a group of 13 physicians who are active in clinical programs, clinical research, and/or quality-performance measurement initiatives in AF. To improve generalization to a broad population, the committee included membership from the United States, France, and Canada. To ensure consistency within the topic of AF, the committee included three members from the ACC/AHA/ESC Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation. To enhance uniformity among different data standards efforts, the committee included one member from the ACC/AHA Task Force on Clinical Data Standards.
B. Review of Literature and Existing Data Definitions
The AF data standards are intended to provide data elements that parallel and complement other ACC and AHA standards, specifically guidelines. The ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation 8 served as the primary evidence-based document that was referenced in the development of data elements and definitions for this statement. The writing committee gathered as many additional candidate data elements and definitions as possible from large clinical trials, national quality-performance measurement initiatives, relevant guidelines, and other national, international, and local cardiovascular data collection efforts. Examples of these data sources include the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AF-FIRM), 7, 9 the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study, 4 the ALFA Study (Etude en Activité Liberale sur le Fibrillation Auriculaire), 10 the Canadian Trial of Atrial Fibrillation, 11, 12 and the Canadian Registry of Atrial Fibrillation (CARAF). 13
C. Prioritizing Data Elements
Once the writing committee reviewed the relevant literature and additional resources, a comprehensive list of potential items was created with the understanding that the final set would be limited to those elements most likely to be needed in data collection efforts. The initial list of data elements was graded according to priority as "high," "medium," or "low." All of the data elements with an average "high" score and a majority of those with an average "medium" score were included in the final set. The remaining elements are not included at this time but may be added and defined in the future.
The subsequent process of writing and revising data element definitions included prioritizing, adding, and removing elements for the purpose of defining the elements in a manner that facilitates consistent data collection.
D. Defining Data Elements
Members of the writing committee were assigned to one of four working groups, each of which was responsible for drafting definitions for a subset of data elements deemed to have priority for the first publication of the AF data standards.
Each writer received a template to assist in drafting the definitions and to provide for a structured format across authors. Writers were encouraged to compose definitions that were broad enough to be applicable in a variety of data collection settings (e.g., inpatient versus outpatient) but specific enough that the data elements could be uniformly interpreted.
To ensure consistency across ACC/AHA clinical data standards and clinical guidelines, previously published definitions were used verbatim whenever appropriate. Furthermore, data element definitions were linked to pre-existing definitions.
E. Writing Considerations for Use
The writing committee determined three major settings in which these data elements may be particularly useful: clinical care, clinical research, and quality-performance measurement.
F. Consensus Development
The ACC/AHA data standards are consensus, team-written documents that are based on judgments of experts in the field of cardiology. This writing committee met several times, both in person and through conference calls, over the course of 18 months to define and refine the data elements and definitions. Consensus was met through meetings, conference calls, and e-mail communications.
G. Peer Review, Public Comment, and Board Approval
The set of AF data elements was reviewed by 6 official reviewers nominated by the ACC, AHA, and the ACC/AHA Task Force on Clinical Data Standards and 10 individual content reviewers (see Appendix A for names and affiliations). To increase its applicability further, the document was posted on the ACC World Wide Web site for a 30-day public comment period between July 30 and August 30, 2003. Response forms were received from 63 individuals, representing 15 countries, including the United States. The document was approved for publication by the governing bodies of the ACC and the AHA. The document has been formally endorsed by the Mediterranean Society of Pacing and Electrophysiology. To determine whether a revision is necessary, these clinical data standards will be reviewed one year after publication and yearly thereafter by the ACC/AHA Task Force on Clinical Data Standards.
H. Document Format
This document is divided into three sections, outlined as follows:
1. Introduction: A description of the methodology for developing the AF clinical data standards and intended goals for their use.
Data Elements and Definitions:
A listing of key data elements and definitions. 3. Reference Guide: A multipurpose resource that maps common data fields between AF data elements and other national/regional data registries and links AF data elements to relevant ACC/AHA guidelines (available online at www.acc.org/clinical/data_standards/ AF/pdf/AF_refguide.pdf).
III. General Considerations of the AF Clinical Data Standards
A. Patient-Oriented Format
Given that AF is a chronic condition, the individual patient is the foundation of this data element set. This focus contrasts with other comparable efforts in which the field of interest may be a procedure (e.g., cardiac catheterization) or an event (e.g., acute coronary syndrome). Thus, the format of these data elements was designed to follow multiple events over time for each individual patient.
B. Balance Between Focus and Comprehensiveness
The writing committee focused on commonly collected data elements that were thought to be most useful for the broadest set of applications. These data standards are not intended to be a comprehensive data element catalog, encompassing every possible data need or use. The writing committee realizes that individual users likely will supplement these elements to suit their individual needs. Conversely, other users will select only a few data elements to collect.
C. Dates
The committee recognizes the critical importance of obtaining dates for most data elements in order to understand the clinical course, therapy, and outcomes of AF for the individual patient and across populations. The exact date (month, day, and year) for all elements and dates of events for prospective data elements should be obtained whenever possible. Because the ability to obtain precise dates of prior events is limited, best estimate of dates should be obtained (e.g., month/year), with emphasis placed on the most current events. The operational format of date collection will vary depending on particular use.
D. Varied Clinical Presentations
These data elements are intended to encompass the full range of patients with AF, including acute and chronic presentations, inpatient and outpatient settings, and scheduled and unscheduled medical care encounters.
E. Balance Between Primary and Summary Data Elements
These data elements consist of both individual data elements (for example, age and left atrial size) and summary elements (for example, New York Heart Association [NYHA] class for heart failure and primary cardiac diagnosis). In general, the committee included summary elements only to supplement primary data elements.
F. Atrial Fibrillation-Specific Elements
When possible, the committee chose data element names and definitions common to other ACC/AHA clinical data standard efforts. However, some elements were designed to specifically meet the needs of patients with AF. The committee wanted to highlight a subset of these AF-specific elements that were particularly noteworthy. These elements appear in bold print in the "Element" column. 
G. Quality of Life
Considerations of quality of life are particularly important in the management of AF. The currently available general health status measures, such as EuroQOL (www.euroqol.org), the SF-36, 14 or the SF-12, 15 are valuable in the breadth of domains that they measure and in their use for comparison across disease states. However, valid and reliable measures focused on the specific health burdens of AF are needed to supplement general health status measures. These focused measures may quantify health status effects of the arrhythmia itself, such as the AF Severity Scale and AF Symptom Burden Checklist used by the Canadian Registry of Atrial Fibrillation 16 ; of complications, such as stroke (National Institutes of Health Stroke Scale 17 ); or of therapy, such as inconvenience and lifestyle changes associated with chronic warfarin therapy. 18 At this point, no single approach to measurement of health status of patients with AF can be recommended.
H. Atrial Flutter and Other Atrial Tachycardias
Although many elements and definitions within this document will apply to patients with atrial flutter and other atrial tachycardias, the identification and definition of the unique features of these rhythms are not within the scope of this document. 
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IV. Atrial Fibrillation Clinical Data Elements and Definitions
Note, boldfaced type in Tables 1 and 2 indicates elements of particular relevance to atrial fibrillation (AF). • Commercial: Refers to all indemnity (fee-for-service) carriers and preferred provider organizations (PPOs).
• HMO: Refers to a health maintenance organization characterized by coverage that provides healthcare services for members on a prepaid basis.
• None: Refers to individuals with no or limited health insurance; thus, the individual is the payer regardless of ability to pay. Only mark "None" when "self" or "none" is denoted as the first insurance in the medical record.
• Non-U.S. Insurance: Refers to individuals who reside in and have health insurance in another country.
Government payer type
If the patient's primary insurance payer for this encounter is "Government," choose the type of government insurance: 
Prior Atrial Fibrillation
Previously used therapeutic strategies
Indicate the types of therapeutic strategies that have been employed previously. Indicate all that apply. (Note: One therapy may apply to more than one category, e.g., amiodarone may be used for rate and rhythm control.)
Rate Control:
*Hybrid is defined as concurrent use of:
• Pharmacological and nonpharmacological therapies or • 2 or more nonpharmacological therapies
Frequency of prior symptomatic episodes
Patient estimate of average interval between symptomatic episodes in days
Duration of prior symptomatic episodes
Patient estimate of duration of each of longest, shortest, and usual symptomatic episodes:
• Less than 48 hours • 48 hours to 7 days • 7 days to 3 months • Longer than 3 months
If more specific short-term intervals are desired, recommend dividing the first category (less than 48 hours) into the following: less than 5 minutes, 5 minutes to less than 6 hours, 6 hours to less than 48 hours.
Successful prior pharmacological cardioversion
List all generic drug names previously used that resulted in the absence of AF or atrial flutter.
Unsuccessful prior pharmacological cardioversion attempted
List all generic drug names previously used that did not result in the absence of AF or atrial flutter.
Successful prior transthoracic electrical cardioversion
Number of previous transthoracic electrical cardioversion sessions attempted that resulted in the absence of AF or atrial flutter. A session may include multiple successive shocks.
Unsuccessful prior transthoracic electrical cardioversion attempted
Number of previous transthoracic electrical cardioversion sessions attempted that did not result in the absence of AF or atrial flutter. A session may include multiple successive shocks.
Successful prior transvenous electrical cardioversion
Number of previous transvenous electrical cardioversion sessions attempted that resulted in the absence of AF or atrial flutter. A session may include multiple successive shocks.
Unsuccessful prior transvenous electrical cardioversion attempted
Number of previous transvenous electrical cardioversion sessions attempted that did not result in the absence of AF or atrial flutter. A session may include multiple successive shocks.
History of ablation for supraventricular arrhythmia
Documented history of ablation for supraventricular arrhythmia. Indications (may have more than one):
• Supraventricular tachycardia (e.g., atrioventricular node re-entry tachycardia, atrioventricular re-entry Assessed via current level of functioning. Categories include:
• Complete/near-complete recovery (able to return to prestroke level of function)
• Mild to moderate deficit (deficits present, but patient can perform activities of daily living, such as dressing and feeding, with no or little assistance) • Severe deficit (requires assistance to complete activities of daily living)
History of other hemorrhage
History of bleeding is defined as either major or minor according to the following criteria:
• Major: Leading to transfusion of at least 2 units of whole blood or erythrocytes, requiring hospitalization or surgery, resulting in permanent disability, or involving a critical anatomic site (retroperitoneal, pericardial, intraspinal, intracranial, atraumatic intra-articular, or intra-ocular bleeding associated with abrupt deterioration of visual acuity). 
Other Cardiovascular History
History of hypertension
Indicate whether the patient has hypertension as documented by:
• History of hypertension diagnosed and treated with medication, diet, and/or exercise • Blood pressure greater than or equal to 140 mm Hg systolic or 90 mm Hg diastolic on at least 2 occasions • Currently undergoing antihypertensive pharmacological therapy More than one of the above may apply. It may be useful to collect more specific information.
Primary reason for encounter
Primary symptom or condition that prompted patient to seek medical attention:
Patient classification of type of AF episodes
Classify patient based on the episodes of AF within the past 12 months:
• First Detected: Patient with a first-detected episode lasting fewer than 6 months • Paroxysmal: Patient with history of 2 or more episodes of paroxysmal AF only • Persistent: Patient with history of 2 or more episodes of persistent AF only • Mixed Paroxysmal/Persistent: Patient with history of 2 or more episodes of AF of either paroxysmal or persistent type • Permanent: Patient with history of 2 or more episodes of AF with at least 1 episode of permanent AF, or a first-detected episode lasting more than 6 months for which no attempt or further attempt to restore sinus rhythm is planned (See "Qualifying Rhythm" for definitions of episode classification.)
Current management strategy
Indicate the types of strategies that are currently being employed. Indicate all that apply:
• Hybrid* *Hybrid is defined as concurrent use of:
• Pharmacological and nonpharmacological therapies or • Two or more nonpharmacological therapies.
Medications on Encounter
Antiarrhythmic drugs and rate-control agents
List generic names of all antiarrhythmic and rate-control medications (including beta-blockers, calcium-channel blockers, and digoxin) that are currently prescribed to patient. Indicate daily dose.
Antithrombotic agents
List generic names for all antithrombotic and antiplatelet medications (including aspirin and clopidogrel) that are currently prescribed to patient. Indicate daily dose.
Angiotensin-converting enzyme inhibitors
List generic names for all angiotensin-converting enzyme inhibitors that are currently prescribed to patient.
Angiotensin receptor blockers
List generic names for all angiotensin receptor blockers that are currently prescribed to patient.
Other cardiac medications
List generic names for all other cardiac medications that are currently prescribed to patient.
Thyroid replacement Indicate whether patient is currently receiving thyroxine and/or T3. Cox-2 inhibitor List Cox-2 inhibitors taken on average more than once per week.
Beta-agonists
List inhaled and oral beta-2-adrenergic agonists taken on average more than once per week.
Physical Examination
Heart rate Heart rate (beats per minute) recorded closest to the time of presentation to the healthcare facility and/or on discharge (for inpatient). Heart rate may be ascertained from ECG tracing or from record of physical examination.
*Note: Each element may be collected multiple times during clinical follow-up. †Boldfaced type indicates elements of particular relevance to atrial fibrillation (AF). ϪAngina that occurred at rest and was prolonged, usually lasting more than 20 minutes ϪNew-onset angina of at least Canadian Cardiovascular Society (CCS) class III severity ϪRecent acceleration of angina reflected by an increase in severity of at least 1 CCS class to at least CCS class III • Myocardial Infarction: For a complete definition, please refer to "Myocardial Infarction (MI)" in the "Other Events" section. Angina class: Canadian Cardiovascular Society (CCS) classification Grading of patient's angina by class (CCS classification system) 21, 22 :
• Class I: Ordinary physical activity, such as walking or climbing stairs, does not cause angina. Angina occurs with strenuous, rapid, or prolonged exertion at work or recreation. • Class II: Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or climbing stairs after meals, or in cold, in wind, or under emotional stress, or only during the few hours after awakening. Angina occurs on walking more than 2 blocks on the level and climbing more than 1 flight of ordinary stairs at a normal pace and in normal condition. 
Cardioversion
Site
Indicate all that apply.
• 
Success of cardioversion attempt
Absence of AF or atrial flutter for at least 10 seconds after shock delivery or at any time after antiarrhythmic drug administration. For pharmacological cardioversion, time frame for assessment will depend on medication and route of administration (e.g., success for intravenous ibutilide may be within 1 hour from the end of infusion, whereas success for oral amiodarone may be within several days).
Pattern of recurrence
After successful conversion:
• Immediate recurrence of AF (returns in less than 2 minutes) • Subacute recurrence of AF (returns between 2 minutes and 14 days)
• Late recurrence of AF (returns after 14 days)
Complications of conversion
Include all complications occurring from the initiation of cardioversion attempt to 28 days after cardioversion. Specify complication and categorize into:
Nonpharmacological Therapy
Supraventricular ablation Indications (may have more than one):
• Supraventricular tachycardia (e.g., AV node re-entry tachycardia, AV re-entry tachycardia, atrial tachycardia)
• Atrial fibrillation • Atrial flutter • Other, specify 
Transient ischemic attack
Acute loss of neurological function caused by an ischemic event with resolution of symptoms by 24 hours after onset.
Non-central nervous system arterial embolic event
Abrupt vascular insufficiency associated with clinical and radiological evidence of arterial occlusion in a vascular bed other than the cerebrovascular system in the absence of other likely mechanisms (e.g., atherosclerosis). In the presence of peripheral arterial disease, diagnosis of embolism requires angiographic demonstration of abrupt arterial occlusion.
Hemorrhagic Events
Intracranial hemorrhage Bleeding into or around the brain:
• Hemorrhagic conversion of a primary ischemic stroke • Subarachnoid hemorrhage • Intracerebral hemorrhage • Other (including subdural and epidural hematomas)
• Unknown Indicate whether documented by CT or MRI.
Other hemorrhage
Bleeding is defined as either major or minor according to the following criteria:
Transfusion
Transfusion of either whole blood or packed red blood cells due to a hemorrhagic event. Note the number of units transfused. Specify type (e.g., whole blood, packed erythrocytes, other blood products) and quantity (units or milliliters).
Procedural intervention to control bleeding Indicate type of procedural intervention (e.g., surgical or catheter-based) performed to control an episode of bleeding. A serious adverse event is defined as one that satisfies any of the following criteria:
ϪResults in death
ϪIs life-threatening (NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.) ϪRequires inpatient hospitalization or prolongation of existing hospitalization ϪResults in persistent or significant disability or incapacity ϪIs a congenital abnormality or birth defect • Nonserious Event • Causality: Relationship of adverse event to the drug as determined by the judgment of the investigator: ϪDefinite ϪProbable ϪPossible • Action Taken:
ϪDrug or device permanently stopped ϪDose reduced or device changed ϪDrug or device temporarily stopped ϪDrug dosage or device not changed
Resource Utilization
Hospital admission
Official admission to a hospital or other acute healthcare facility. Include dates of admission and discharge.
Primary reason for admission
Primary diagnosis of the event that prompted admission, as determined by the judgment of the investigator, given as text description and latest ICD code (e.g., ICD-9 or ICD-10). May be the same as principal discharge diagnosis.
Number of days in intensive care
Number of days in intensive care Principal discharge diagnosis Principal discharge diagnosis listed in official record (e.g., used for reimbursement), given as text description and latest ICD code (e.g., ICD-9 or ICD-10) Emergency department visit Include visits not resulting in hospitalization.
Procedures performed
In addition to the procedure information obtained elsewhere in the data set (e.g., ECG, ablation, cardioversion, pacemaker/implantable cardioverter-defibrillator implant, echocardiography), other important procedures to document utilization include:
Other Events
Myocardial infarction Either one of the following criteria satisfies the diagnosis for an acute, evolving, or recent MI:
• Typical rise and gradual fall (troponin) or more rapid rise and fall (creatine kinase-MB) of biochemical markers of myocardial necrosis with at least 1 of the following:
ϪIschemic symptoms ϪDevelopment of pathological Q waves on the ECG ϪECG changes indicative of ischemia (ST-segment elevation or depression) ϪCoronary artery intervention (e.g., coronary angioplasty) preceding enzyme rise Or
• Pathological findings of an acute MI 
